AC Immune S.A.
NASDAQ:ACIUBiotechnology
Healthcare
$2.10 +1.71%
+$0.04 today
- Market cap
- $213.72M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
52W Low $1.65High $4.00
Volume 0.08M
Average 0.32M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$66.15M
FY 2025 · Annual
Investing Cash Flow
$60.69M
FY 2025 · Annual
Financing Cash Flow
-$974,143.00
FY 2025 · Annual
Cash Flow Statement
CHF
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73M) | (70.75M) | (54.23M) | (50.92M) | (67.28M) |
| Depreciation & Amortization | 2.41M | 2.36M | 2.22M | 2.16M | 2.39M |
| Deferred Income Tax | 130K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.13M | 3.33M | 4.37M | 5.47M | 0 |
| Change in Working Capital | 6.84M | (8.43M) | (15.16M) | 107.51M | (6.47M) |
| Accounts Receivables | (99K) | 603K | (14.8M) | 13.55M | 877.68K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | (565.39K) |
| Other Working Capital | 6.94M | (9.04M) | (360K) | 93.96M | (6.78M) |
| Other Non-Cash Items | (6.2M) | (72K) | 2.41M | 1.61M | 5.21M |
| Operating Cash Flow | (65.69M) | (73.57M) | (60.41M) | 65.84M | (66.15M) |
| Capital Expenditures | (2.64M) | (1.24M) | (801K) | (576K) | (859.54K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 14.33K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 61.69M |
| Other Investing Activities | (51.03M) | 25M | 66.45M | (104.71M) | (162.36K) |
| Investing Cash Flow | (53.66M) | 23.76M | 65.65M | (105.29M) | 60.69M |
| Debt Repayment | 22.95M | (569K) | (548K) | (683K) | (1.03M) |
| Common Stock Issued | 17.8M | 7K | 43.8M | 111K | 5.73K |
| Common Stock Repurchased | 0 | (8K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6K) | (776K) | 0 | (548K) | 46.13K |
| Financing Cash Flow | 40.75M | (1.35M) | 43.25M | (1.12M) | (974.14K) |
| Effect of Forex Changes | (70K) | 521K | (1.58M) | (1.65M) | 1.51M |
| Net Change in Cash | (78.68M) | (50.63M) | 46.91M | (42.22M) | (4.92M) |
| Free Cash Flow | (68.32M) | (74.81M) | (61.21M) | 65.27M | (67.01M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$67.3M
+ D&A$2.4M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$6.5M
+ Other Non-Cash$5.2M
= Operating Cash Flow-$66.1M
- Capex-$859.5K
= Free Cash Flow-$67.0M
Analysis
FY2025 free cash flow is -$67.0M. FCF conversion is 99.6% of net income. Operating cash flow was -$66.1M, with capex of -$859.5K. The largest bridge item is Working Capital at -$6.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 4, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 9, 2026 | |
| 3/A | 3/A filing | Oct 9, 2026 | |
| 6-K | 6-K filing | Oct 2, 2026 | |
| 6-K | 6-K filing | Sep 23, 2026 |
Does ACIU generate free cash flow?
AC Immune S.A. (ACIU) generated -$67.01M of free cash flow in fiscal 2025.
How much operating cash flow does ACIU produce?
Operating cash flow was -$66.15M, before capital expenditures of $859,541.00.
Continue the stock analysis
Jump to another research area for this company.